- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02428842
Biomarker Evaluation in Advanced Stage Cervical Cancer by an International Working Group. Tumor Stages (1B1 - 4) (BIO-RAIDs)
January 19, 2023 updated by: Institut Curie
Prospective Multicentric European trial for Cervical cancer, not previously treated, with tumour biopsies, and blood collection for molecular analysis at predetermined time points.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
419
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
France
-
-
Angers, France, 49933
- Institut de Cancérologie de l'Ouest - Paul Papin
-
Bordeaux, France
- Institut Bergonié
-
Créteil, France, 94010
- Centre Hospitalier Intercommunal de Créteil - CHI Créteil
-
Dijon, France, 21079
- Centre Georges François Leclerc
-
Lyon, France
- Centre Léon Bérard
-
Montpellier, France, 34298
- Institut Régional du Cancer de Montpellier - Val D'Aurelle
-
Nancy, France
- Institut de Cancérologie de Lorraine - ICL
-
Nantes, France
- Institut de Cancérologie de l'Ouest - RENE GAUDUCHEAU
-
Nice, France, 06189
- Centre Antoine Lacassagne
-
Paris, France, 75015
- Hôpital Européen Georges Pompidou
-
Paris, France
- Hopital Tenon
-
Paris, France, 75248
- Insitut Curie
-
Saint-Cloud, France
- Institut René Huguenin
-
Strasbourg, France, 67065
- Centre Paul Strauss
-
Vandœuvre-lès-Nancy, France, 54519
- Institut de Cancérologie de Lorraine- ICL NANCY
-
Villejuif, France, 94805
- Institut de Cancérologie Gustave roussy
-
-
Ile De France
-
Paris, Ile De France, France, 75877
- Groupe Hospitalier Bichat
-
-
-
Germany
-
-
Hannover, Germany, 30625
- Mhh Hanover - Hanover Medical School
-
-
-
Netherlands
-
-
Amsterdam, Netherlands, 1006 BE
- Netherland Cancer Institute - Antoni van Leeuwenhoek (NKI-AVL)
-
-
Meibergdreef
-
Amsterdam, Meibergdreef, Netherlands, 91105 AZ
- Amsterdam Medical Center (AMC)
-
-
-
Romania
-
-
Brasov, Romania, 500091
- Teo Health S.A. - Spitalul Sf. Constantin
-
Oradea, Romania, 410469
- Spitalul Clinic Municipal "Gavril Curteanu"
-
Timisoara, Romania, 300041
- Clinica de radioterapie
-
-
-
Serbia
-
-
Sremska Kamenica, Serbia, 21204
- Clinic for operative oncology, Institute of oncology of Vojvodina
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- No prior treatment for cervical cancer.
- FIGO Stage IB1 to IVB; all histological subtypes (excluding neuro-endocrine type).
- Pelvic MRI available or planned before the start of treatment, , if FIGO ≥ IB2. and optional for IB1 stage
- Possibility to communicate imaging data by CD-ROM (format DICOM 3.0 or more).
- Disease amenable to biopsy (3 tumour samples are mandatory prior to treatment).
- Age ≥ 18 years.
- ECOG (Eastern Cooperative Oncology Group) 0-2.
- Life expectancy > 6 months.
- Patient eligible for standard treatment (according to standards of each center).
- Patient having health care insurance.
- Informed and signed consent by patient.
(DICOM = Digital Imaging and Communications in Medicine)
Exclusion Criteria:
- Patient enrolled in a clinical trial involving an investigative new agent.
- Co morbidity, preventing patient to tolerate the proposed standard treatment.
- Past history of invasive cancer over the 5 years preceding entry in the present trial (except basal cell carcinoma and carcinoma in situ of the cervix).
- Impossibility to carry out evaluation by MRI (patient claustrophobic, pacemaker, metallic implant, non availability, other), ), if FIGO ≥ IB2 .
- Patient deprived from ability to decide on her own.
- Patient unable to have a regular follow up for geographical, social or psychological reasons.
- Pregnancy or patient old enough to procreate and not using effective contraceptive method.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Tumor biopsies and blood sampling
Patient will undergo standard care with tumor and blood sampling before and after treatment. Blood and tumor sampling will also be performed at disease progression/relapse. |
Tumor biopsies will be performed before and after treatment.
Blood sampling will be performed before and after treatment.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Correlation between tumor biological profile and treatment response.
Time Frame: up to 6 months
|
Dominant mutations and activation pathways in cervical cancers is assessed from tumor biopsies.
|
up to 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression Free Survival evaluation
Time Frame: up to 18 months
|
Number of patient with no local/metastasis relapse 18 months after end of primary treatment course.
|
up to 18 months
|
Standard treatment description (Description of primary treatment course regarding : - Initial FIGO ( International Federation of Gynecology and Obstetrics ) staging at baseline - Geographic location(country)
Time Frame: up to six months
|
Description of primary treatment course regarding :
|
up to six months
|
Standard treatment's side effects description (assessed by compiling grade 3 and 4 sides effects during and after treatment (according to NCI CTCAE v4.03 scale - National Cancer Institute Common Toxicity Criteria for Adverse Effects)
Time Frame: up to 6 months
|
Description of standard treatment's side effects will be assessed by compiling grade 3 and 4 sides effects during and after treatment (according to NCI CTCAE v4.03 scale
|
up to 6 months
|
Molecular tumor alterations description (Description of molecular tumor alterations regarding geographic location (country)
Time Frame: up to 24 months
|
Description of molecular tumor alterations regarding geographic location (country)
|
up to 24 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 24, 2013
Primary Completion (Actual)
November 21, 2018
Study Completion (Actual)
October 20, 2020
Study Registration Dates
First Submitted
February 10, 2015
First Submitted That Met QC Criteria
April 23, 2015
First Posted (Estimate)
April 29, 2015
Study Record Updates
Last Update Posted (Actual)
January 20, 2023
Last Update Submitted That Met QC Criteria
January 19, 2023
Last Verified
January 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IC 2013-02 BIO-RAIDs
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact [email protected]. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cervical Cancer
-
NCT04743674Not yet recruiting
-
NCT04242823Active, not recruitingConditions: Cervical Cancer, Prevention
-
NCT02465060Active, not recruitingConditions: Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colon Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Esophageal Carcinoma, Gastric Carcinoma, Glioma, Head and Neck Carcinoma, Kidney Carcinoma, Liver and Intrahepatic Bile Duct Carcinoma, Lung Carcinoma, Lymphoma, Malignant Uterine Neoplasm, Melanoma, Ovarian Carcinoma, Pancreatic Carcinoma, Plasma Cell Myeloma, Prostate Carcinoma, Rectal Carcinoma, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Cervical Carcinoma, Recurrent Colon Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Glioma, Recurrent Head and Neck Carcinoma, Recurrent Liver Carcinoma, Recurrent Lung Carcinoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Melanoma, Recurrent Ovarian Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Plasma Cell Myeloma, Recurrent Prostate Carcinoma, Recurrent Rectal Carcinoma, Recurrent Skin Carcinoma, Recurrent Thyroid Gland Carcinoma, Recurrent Uterine Corpus Cancer, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Plasma Cell Myeloma, Skin Carcinoma, Thyroid Gland Carcinoma, Uterine Corpus Cancer
-
NCT05709769Not yet recruitingConditions: Cervical Cancer, Malnutrition
-
NCT05622760CompletedConditions: Uterine Cervical Neoplasms, Early Detection of Cancer, Anxiety, Clinical Trial
-
NCT05614453Not yet recruitingConditions: Metastatic Cervical Cancer
-
NCT05438420RecruitingConditions: Esophageal Cancer, Gastric Cancer, Hepatocellular Cancer, Cervical Cancer
-
NCT05092022Not yet recruitingConditions: Cervical Cancer Screening
-
NCT04895709RecruitingConditions: Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, Microsatellite Stable Colorectal Cancer, Non-Small-Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Urothelial Carcinoma, Pancreatic Adenocarcinoma, Melanoma, Ovarian Neoplasms, Triple Negative Breast Neoplasms
-
NCT05111574RecruitingConditions: Anal Melanoma, Bladder Melanoma, Cervical Melanoma, Esophageal Melanoma, Gallbladder Melanoma, Mucosal Melanoma, Mucosal Melanoma of the Head and Neck, Mucosal Melanoma of the Urinary System, Oral Cavity Mucosal Melanoma, Penile Mucosal Melanoma, Rectal Melanoma, Recurrent Mucosal Melanoma, Sinonasal Mucosal Melanoma, Stage II Vulvar Cancer AJCC v8, Stage III Vulvar Cancer AJCC v8, Stage IV Vulvar Cancer AJCC v8, Urethral Melanoma, Vaginal Melanoma, Vulvar Melanoma
Clinical Trials on Tumor biopsies
-
NCT00260585RecruitingConditions: Esophageal Cancer, Gastroesophageal Reflux Disease (GERD), Esophageal Diseases, Hiatal Hernia, Esophageal Achalasia
-
NCT02428842CompletedConditions: Cervical Cancer
-
NCT03946358RecruitingConditions: Squamous Cell Carcinoma of the Head and Neck, Anal Canal Cancer, Cervical Cancer
-
NCT03017573RecruitingConditions: Ovarian Cancer, Triple-Negative Breast Cancer, Head and Neck Cancer
-
NCT01894451Completed
-
NCT03865511RecruitingConditions: Non-small Cell Lung Cancer
-
NCT00512551CompletedConditions: Cervical Cancer
-
NCT02894853Unknown statusConditions: Carcinoma, Non-Small-Cell Lung
-
NCT02111889CompletedConditions: Disseminated Malignant Neoplasm
-
NCT00943891Unknown statusConditions: Colorectal Cancer, Nasopharyngeal Cancer